Immunoassay Market – Snapshot
The global immunoassay market is expanding at a rapid pace due to high prevalence and rise in incidence of chronic, acute, and infectious diseases across the globe. The market was valued at US$ 16.54 Bn in 2017 and is projected to expand at a CAGR of 6.2% from 2018 to 2026 to reach US$ 28.61 Bn by 2026. The global immunoassay market is driven by technological advancements in the development of new immunoassays and analyzers and demographic and life changes favoring rapid, preventive, and predictive diagnosis.
An immunoassay is a biochemical test conducted in IVD laboratories for the detection of presence of specific molecules in a solution with the use of an antigen or antibody. Immunoassay diagnostics tests have been widely used for more than 40 years in hospitals, diagnostic laboratories, blood banks, and research laboratories. Immunoassays have a number of applications in in vitro diagnostics for the diagnosis of various chronic as well as infectious diseases, prediction of disease course, framing the treatment, and monitoring the effectiveness of the therapy. Immunoassays are widely used in the life science industry for studying various biological systems by means of analysis of different biological molecules such as proteins, hormones, and antibodies.
High prevalence and rise in incidence rate of chronic and infectious diseases across the globe are projected to be the key drivers of the global immunoassay market during the forecast period.
Endocrinological diseases such as thyroid dysfunction, diabetes mellitus, osteoporosis, and others are on the rise owing to changing lifestyles. According to the International Diabetes Federation (IDF), in 2015, 415 million people were affected with diabetes worldwide. Various chronic diseases such as chronic respiratory diseases (CRD), diabetes, chronic kidney diseases (CKD), cancer, cardiac stroke, and neurological disorders are leading causes of disability and mortality across the globe. According to the International Agency for Research on Cancer (IARC), more than 14.1 million new cancer cases were diagnosed in 2012, and the global burden is estimated to increase by 21.7 million new cancer cases by the end of 2030. Demographic and lifestyle changes are fueling demand for rapid, preventive, and predictive diagnosis in developed countries. As part of preventive health care, elderly people and people with lifelong diseases such as diabetes, respiratory disorders, and cancer frequently require various medical tests such as blood tests and urine test. Thus, rapidly growing geriatric population across the globe requiring frequent medical tests is likely to be a key driver of the immunoassay market during the forecast period.
Development of integrated systems with complete automation for diagnosis of viral structural changes and new viral epidemics are anticipated to present significant opportunities in the global immunoassay market during the forecast period. With a rise in consolidation among diagnostic laboratories, test volumes are projected to increase. This is expected to boost demand for more integrated multi component systems that can offer solutions such as complete automated sample handling & post process sample storage, data integration with lab automation platform, and remote access monitoring and control. There are few systems available in the market that offer these features. One such system is Siemens Healthineer’s Atellica analyzer system that was introduced in 2016 and received FDA approval in 2017. Recent approvals from the U.S. FDA reflect increasing investments from key players for the development of point-of-care automated immunoassay analyzer systems and the rise in demand from end-users.
The global immunoassay market has been segmented based on technology, product, application, end-user, and region. In terms of technology, the global market has been classified into chemiluminescence immunoassay (CLIA), enzyme-linked immunoassay (ELISA), enzyme-linked immunofluorescent assay (ELFA), radioimmunoassay (RIA), and others. The others segment includes microarray, biochip assays, and counting immunoassay. The chemiluminescence immunoassay (CLIA) segment dominated the global market in 2017 and is projected to gain market share by the end of 2026. High sensitivity and lower cost of CLIA are estimated to drive the segment during the forecast period. Moreover, availability of a wide range of assays and high throughput of CLIA analyzers are likely to propel the segment from 2018 to 2026. In terms of product, the global market has been categorized into immunoassay analyzers and consumables. The consumables segment includes immunoassay kits and reagents, calibrators, controls, diluents, buffers, and wash solutions. The consumables segment is estimated to hold around 80% share of the global immunoassay market by the end of 2026.
Based on application, the global immunoassay market has been divided into infectious diseases, endocrinology, oncology, cardiology, orthopedics, and others. The others segment includes autoimmune disorders, therapeutic drug monitoring, gastrointestinal disorders and stool testing, and allergy testing. The infectious disease segment dominated the global immunoassay market in 2017 accounting for more than 25% of the market share. The endocrinology segment is projected to expand at a rapid CAGR during the forecast period.
In terms of end-user, the global immunoassay market has been divided into hospitals & diagnostics laboratories, blood banks, and others. The others segment includes academic and research institutes, pharmaceutical and biotechnology companies, and forensic laboratories. The hospitals & diagnostic laboratories segment accounted for a leading share of the global market and is projected to continue to dominate the market during the forecast period. Rapid increase in the number of health care institutions in emerging countries, large test volume for various diseases, and expansion of laboratory services contributed to the dominant share of the segment in 2017. The blood bank segment held a prominent share of the global immunoassay market in 2017.
Based on region, the global immunoassay market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for a dominant share of the global immunoassay market, accounting for more than 35% share in 2017. Europe held a prominent share of the global market in 2017. Well-established health care infrastructure, rapidly increasing geriatric population, and large base of pharmaceutical and biotechnology industries has led to dominant shares of North America and Europe. The market in Asia Pacific is projected to expand at a rapid CAGR during the forecast period owing to rise in foreign direct investment in the health care and life science industry, rapidly increasing number of hospitals and diagnostic laboratories in the region, and large patient population with chronic and infectious diseases.
The global immunoassay market is fragmented, with a large number of companies accounting for majority share in respective regions. Major players operating in the global market include F. Hoffmann-La Roche Ltd., Danaher Corporation, Abbott Laboratories, and Siemens Healthineers. Manufacturers are adopting strategies of mergers and acquisitions with parallel companies to strengthen their product portfolio and geographic reach. Other prominent players operating in the global market include Becton, Dickinson and Company, Ortho Clinical Diagnostics, bioMérieux SA, Sysmex Corporation, and DiaSorin S.p.A.
Immunoassay Market – Overview
This report on the immunoassay market studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in manufacturing, commercializing, and providing immunoassays and new entrants planning to enter the market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments considered in the scope of the study. This section also provides the overall information and data analysis of the global immunoassay market regarding leading market segments based on technology, product, application, end-user, and region.
The global immunoassay market has been classified based on technology, product, application, end-user, and region. Based on product, the global market has been segmented into chemiluminescence immunoassay (CLIA), enzyme-linked immunoassay (ELISA), enzyme-linked immunofluorescent assay (ELFA), radioimmunoassay (RIA), and others. In terms of product, the market has been categorized into analyzer and consumables. Based on application, the global immunoassay market has been divided into infectious disease, endocrinology, oncology, cardiology, orthopedics, and others. In terms of end-user, the market has been segmented into hospitals and diagnostics laboratories, blood banks, and others.
Each of the market segments have been extensively divided based on market-related factors such as rise in incidence rate and prevalence of acute, chronic, and infectious diseases; technological advancements in health care diagnostics; and emerging trends in the health care, pharmaceutical, and biotechnology industries. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast in terms of US$ Mn for each segment has been provided for the period from 2016 to 2026. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2018 to 2026, considering 2017 as the base year.
The market overview section of the report explores market dynamics such as drivers, restraints, opportunities, and key trends that have a strong impact on the immunoassay market and could influence it in the near future. Market attractiveness analysis has been provided in an overview section to explain the intensity of competition in the market across different regions. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. These factors are likely to help market players take strategic decisions to strengthen their positions and expand their shares in the global immunoassay market.
Based on region, the immunoassay market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions has been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The report also provides market size and forecast for major countries with each product and end-user in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market growth and future opportunities has been provided in the market overview section. This section of the report also provides the market attractiveness analysis and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global immunoassay market.
Major players operating in the global Immunoassay market are F. Hoffmann-La Roche AG, Danaher Corporation, Abbott Laboratories, Siemens Healthineers (Siemens AG), Thermo Fisher Scientific Inc., Merck KGaA, Becton, Dickinson and Company, Ortho Clinical Diagnostics (a part of Carlyle Group), bioMérieux SA, Sysmex Corporation, and DiaSorin S.p.A..
The global Immunoassay market is segmented as follows:
Global Immunoassay Market Revenue, by Technology
- Chemiluminescence Immunoassay (CLIA)
- Enzyme-linked Immunoassay (ELISA)
- Enzyme-linked Immunofluorescent Assay (ELFA)
- Radioimmunoassay (RIA)
Global Immunoassay Market Revenue, by Product
Global Immunoassay Market Revenue, by Application
- Infectious Disease
Global Immunoassay Market Revenue, by End-user
- Hospitals and Diagnostics Laboratories
- Blood Banks
Global Immunoassay Market Revenue, by Region
- North America
- Rest of Europe
- Asia Pacific
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America (LATAM)
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of Middle East & Africa